Journals / Turkish Neurosurgery / 2009 / Cilt: 19 - Sayı: 4

Orta serebral oklüzyon modeli ile oluşturulan serebral iskemi hasarında meksiletinin koruyucu etkisi

The preventive effect of mexiletine on cerebral ischemic injury following experimental middle cerebral artery occlusion

Pages
367–373
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RESULTS: The results showed statistically significant differences between the treatment (81.98 ± 12.58 mm?), control (121.57 ± 11.41 mm?) and sham (116.08 ± 12.36 mm?) groups (p < 0,0001), respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Previous studies demonstrated that mexiletine has some important features in the prevention of ischemic brain injury such as sodium and calcium canal blockage and free radical occurrence.
📊
Key Findings & Data:MATERIAL and METHODS: Experiments were performed on 30 adult male Sprague- Dawley rats (285-425 g).
💡
Conclusion & Impact:RESULTS: The results showed statistically significant differences between the treatment (81.98 ± 12.58 mm?), control (121.57 ± 11.41 mm?) and sham (116.08 ± 12.36 mm?) groups (p < 0,0001), respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: Previous studies demonstrated that mexiletine has some important features in the prevention of ischemic brain injury such as sodium and calcium canal blockage and free radical occurrence. Our aim was to investigate the effects of mexiletine on ischemic brain injury. MATERIAL and METHODS: Experiments were performed on 30 adult male Sprague- Dawley rats (285-425 g). Left middle cerebral artery occlusion following microcraniectomy and simultaneous bilateral carotid artery occlusion were performed. Three different treatments were included in this study: (a) &#8220;naïve&#8221; control group (no drug applied; n = 10); (b) &#8220;sham surgery&#8221; control group (only saline was applied; n = 10); and a (c) &#8220;treatment group (n = 10) where mexiletine was applied. After 24 h from ischemic insult, all rats were decapitated and prepared for immunocytochemical and histopathological analyses. Cerebral infarct volumes were calculated and compared using ANOVA and a Post- Hoc Bonferroni test in each group statistically. RESULTS: The results showed statistically significant differences between the treatment (81.98 ± 12.58 mm?), control (121.57 ± 11.41 mm?) and sham (116.08 ± 12.36 mm?) groups (p < 0,0001), respectively. CONCLUSION: Mexiletine should be considered as an alternative medication for prevention and treatment of ischemic brain injury due to its multipotent effects.

Özet

AMAÇ: Yapılmış çalışmalarda meksiletinin sodyum ve kalsiyum kanal blokajı ve serbest radikal oluşumunu engelleyerek iskemik beyin hasarında koruyucu etkisinin olduğu gösterilmiştir. Bu çalışmada beyinin iskemik hasarında meksiletinin etkisi araştırılmıştır. YÖNTEM ve GEREÇ: Çalışmada 30 yetişkin erkek Sprague-Dawley türü sıçan kullanıldı (285-425 g). Mikrokraniyotomi sonrası orta serebral arter oklüzyonu ve simultane bilateral karotid arter oklüzyonu uygulandı. Üç ayrı uygulama yapıldı: (a) “naïve” kontrol grubu (ilaç uygulanmadı; n = 10); (b) “sham grubu” kontrol grubu (sadece salin solüsyonu; n = 10); ve (c) “tedavi grubu (n = 10) meksiletin uygulandı. İskemiden 24 saat sonra tüm sıçanlar dekapite edilerek immünohistokimyasal ve histopatolojik inceme için hazırlandı. Serebral infarkt hacimleri hesaplandı ve sonuçlar ANOVAve Post- Hoc Bonferroni test ile istatistiksel olarak değerlendirildi. BULGULAR: Sonuçlar karşılaştırıldığında tedavi grubu ile (81,98 ± 12,58 mm?), kontrol (121,57 ± 11,41 mm?) ve sham (116,08 ± 12,36 mm?) grupları arasında sırasıyla anlamlı farklılık saptandı (p < 0,0001). SONUÇ: Meksiletin iskemik beyin hasarında hem koruyucu hem de tedavi edici etkisi nedeniyle iyi bir alternatif olarak kabul edilmelidir.

🔖

Cite This Article

YILMAZ, C., ÖZGER, Ö., KARATAŞ, S., CANSEVER, T., AKAR, A., GÜLŞEN, S., ALTINÖRS, N., CANER, H. (2009). Orta serebral oklüzyon modeli ile oluşturulan serebral iskemi hasarında meksiletinin koruyucu etkisi. Turkish Neurosurgery, Cilt: 19 - Sayı: 4, 367–373. https://ajindex.com/articles/405187

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Arboix A, Garcia-Eroles L, Massons J, Oliveres M, Comes E: Predictive factors of early seizures after acute cerebrovascular disease. Stroke 28:1590-94, 1997 2. Azcoitia I, Sierra A, Segura-Garcia ML: Neuroprotective effects of estradiol in the adult rat hippocampus. Interaction with insulin-like growth factor-1 signaling. J Neurosci Res 58:815-822, 1999 3. Callaway J, Knight M, Watkins D, Beart P, Jarrott B: Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke 30:2704-2712, 1999 4. Canan S, Şahin B, Odacı E, Ünal B, Aslan H, Bilgiç S, Kaplan S: Toplam Hacim, Hacim Yoğunluğu ve Hacim Oranlarının Hesaplanmasında Kullanılan Bir Stereolojik Yöntem: Cavalieri Prensibi. THBV Türkiye Klinikleri Tıp Bilimleri Dergisi 22: 7-14, 2002 5. Caner H, Kwan AL, Bavbek M, Kilinc K, Durieux M, Lee K, Kassell NF: Systemic administration of mexiletine for attenuation of cerebral vasospasm following experimental subarachnoid haemorrhege. Acta Neurochir 142:455-461, 2000 6. Carter A: The importance of voltage-dependent sodium channels in cerebral ischaemia. Amino Acids 14:159-69, 1998 7. Chan PH: Role of oxidants ischemic brain damage. Stroke 27:1124-1149, 1996 8. Chang CZ, Winardi D, Loh JK, Kung SS, Howng SL, Jeng AY, Kwan AL: Alteration of reperfusion injury in the rat neocortex by a potent antioxidant mexiletine. Acta Neurochir (Wien) 144: 189-193, 2002 9. De Luca A, Pierno S, Natuzzi F, Franchini C, Duranti A, Lentini G, Tortorella V, Jockusch H, Camerino DC: Evaluation of the antiarrhythmic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse. J Pharmacol Exp Ther 282:93-100, 1997 10. Demirpençe E, Caner H, Bavbek M, Kılınç K: Antioxidant action of the antiarrhythmic drug mexiletine in brain membranes. Jpn J Pharmacol 81:7-11, 1999 11. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391- 397, 1999 12. Graham S, Chen J, Lan J, Leach M, Simon R: Neuroprotective effects of usedependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion. J Pharmacol Exp Ther 269:854-859, 1994 13. Gundersen HJG, Boysen M, Reith A. Comparison of semiautomatic digitizer-tablet and simple point counting performance in morphometry. Virchows Arch B Cell Pathol Incl Mol Pathol 37:317-3